en · de · es
analytical-notes.peptides5388.com › Info › Sr9009 Identity And Mechanism — Hands-On Walkthrough

Sr9009 Identity And Mechanism — Hands-On Walkthrough

By Editorial Desk · published 2026-03-11 · last reviewed 2026-03-27 · Info

Stenabolic is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2026-03-27. Where a claim depends on a specific study, the study is described rather than over-claimed.

SR9009 Identity and Mechanism

SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

Analytical Detection and Storage

Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.

Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.

Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.

Sr9009 at a glance

PropertyValueNotes
Common nameSR9009Also marketed informally as Stenabolic
Chemical classSynthetic REV-ERB agonistBinds REV-ERBα and REV-ERBβ
Molecular formulaC24H30ClN3O4SApproximate molecular weight 492 g/mol
CAS Registry Number1379686-30-2Identifier for the parent compound
Regulatory statusNot approved for human useProhibited in sport by WADA

Analytical Detection and Regulatory Status

Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.

Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.

Related pages on this site

SR9009 Background and Receptor Mechanism

SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.

Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.

SR9009 Background and Mechanism

Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.

Notes from published material

On February 25, 2007, the Commonwealth of Virginia resolved to 'profoundly regret' and apologize for its role in the institution of slavery. Unique and the first of its kind in the U.S., the apology was unanimously passed in both Houses as Virginia approached the 400th anniversary of the founding of Jamestown. On August 24, 2007, Mayor of London Ken Livingstone issued a public apology for London's role in Atlantic slave trade, which took place at an event commemorating the 200th anniversary of the British slave trade's abolition. In his speech, Livingstone described the slave trade as "the racial murder of not just those who were transported but generations of enslaved African men, women and children. To justify this murder and torture black people had to be declared inferior or not human... We live with the consequences today." City officials in Liverpool, which was a large slave trading port, apologized in 1999. On July 30, 2008, the United States House of Representatives passed a resolution apologizing for American slavery and subsequent discriminatory laws. In June 2009, the U.S. Senate passed a resolution apologizing to African-Americans for the "fundamental injustice, cruelty, brutality, and inhumanity of slavery". The news was welcomed by President Barack Obama, the nation's first president of African descent. Some of President Obama's ancestors may have been slave owners. In 2010, Libyan leader Muammar Gaddafi apologized for Arab involvement in the slave trade, saying: "I regret the behavior of the Arabs...

== Aging == Thailand in 2012 ranked number three of 66 nations with the most rapidly aging populations (1=most rapidly aging, 66=least rapidly aging). The Global AgeWatch Index for 2015 ranked Thailand 34 of 96 nations (1=best, 96=worst). The AgeWatch Index purports to measure "...how well...aging populations are faring."

=== Systematics === The emu was long classified, with its closest relatives the cassowaries, in the family Casuariidae, part of the ratite order Struthioniformes. An alternate classification was proposed in 2014 by Mitchell et al., based on analysis of mitochondrial DNA. This splits off the Casuariidae into their own order, the Casuariiformes, and includes only the cassowaries in the family Casuariidae, placing the emus in their own family, Dromaiidae. The cladogram shown below is from their study.

=== Sub 1-GHz === D7A utilizes the 433, 868 and 916 MHz frequencies, which are globally available and license-free. Sub 1-GHz is ideal for wireless sensor networking applications, since it penetrates concrete and water, but also has the ability to propagate over very long ranges without requiring a large power draw on a battery. The low input current of typical tag configurations allows operating on coin cell or thin-film batteries.

Sources: en.wikipedia.org

Background from the literature

== Role of the clinical data manager in a clinical trial == Job profile acceptable in CDM: clinical researcher, clinical research associate, clinical research coordinator etc. The clinical data manager plays a key role in the setup and conduct of a clinical trial. The data collected during a clinical trial form the basis of subsequent safety and efficacy analysis which in turn drive decision making on product development in the pharmaceutical industry. The clinical data manager is involved in early discussions about data collection options and then oversees development of data collection tools based on the clinical trial protocol. Once subject enrollment begins, the data manager ensures that data are collected, validated, complete, and consistent. The clinical data manager liaises with other data providers (e.g. a central laboratory processing blood samples collected) and ensures that such data are transmitted securely and are consistent with other data collected in the clinical trial. At the completion of the clinical trial, the clinical data manager ensures that all data expected to be captured have been accounted for and that all data management activities are complete. At this stage, the data are declared final (terminology varies, but common descriptions are "Database Lock", “Data Lock” and "Database Freeze"), and the clinical data manager transfers data for statistical analysis.

If a designer is interested only in the best sequence, the protein design algorithm only requires the lowest-energy conformation of the lowest-energy sequence. In these cases, the amino acid identity of each rotamer can be ignored and all rotamers belonging to different amino acids can be treated the same. Let ri be a rotamer at residue position i in the protein chain, and E(ri) the potential energy between the internal atoms of the rotamer. Let E(ri, rj) be the potential energy between ri and rotamer rj at residue position j. Then, we define the optimization problem as one of finding the conformation of minimum energy (ET):

=== European Commission fine === On 19 June 2013, the European Commission imposed a fine of €93.8 million on the Danish pharmaceutical company Lundbeck, plus a total of €52.2 million on several generic pharmaceutical-producing companies. This was in response to Lundbeck entering an agreement with the companies to delay their sales of generic citalopram after Lundbeck's patent on the drug had expired, thus reducing competition in breach of European antitrust law.

According to Morning Consult polling, Biden maintained an approval rating above 50% during his presidency's first eight months. In August 2021, it began to decline, reaching the low forties by December. This was attributed to the Afghanistan withdrawal, increasing hospitalizations from the Delta variant, high inflation and gas prices, disarray within the Democratic Party, and a general decline in popularity customary in politics. In 2023, Biden's approval rating was the lowest of any modern U.S. president after three years in office. Gallup, Inc. found Biden's approval ratings to be consistently above 50% during his first few months in office, but by August, his ratings began to decline. He had a 98% approval rating from Democrats in February 2021, but by December only 78% approved of his presidency. By October 2023, his rating among Democrats had reached a record low of 75%. His approval rating among Republicans has been consistently in the single digits, aside from his first few months in office. Gallup also noted that Biden's public support eroded each year he was in office: he averaged 49% approval in his first year, 41% in his second, 40% in his third, and 39% in 2024. In July 2024, just before he withdrew from the presidential election, Gallup found his approval rating had fallen to an all-time low of 36%. Gallup found that Biden had an average approval rating of 42.2% throughout his presidency, lower than all other presidents' except Trump's in his first term, at 41.1%.

==== Science and Technology Center ==== The Science and Technology Center (S/T) is a highly challenging four-year curriculum which provides college-level academic experiences in science, mathematics, and technology. The program is not a true magnet program, as students are admitted into the S/T program based on competitive examination only, as opposed to the standard magnet lottery process. Of twenty-eight possible credits, a student is required to obtain a minimum of thirteen credits in specific mathematics, pre-engineering technology, research and science courses. In grades nine and ten, the program consists of common experiences courses for all student. In grades eleven and twelve, each student must choose course work from at least one of four major study areas. Students are expected to be enrolled in a full schedule of classes during the entire four-year program. External experiences are possible and encouraged, but must be a direct extension or enrichment of the Science and Technology Program, and have the recommendation of the Science and Technology Center Coordinator prior to approval by the principal. The program is offered at three centers — Eleanor Roosevelt High School in northern Prince George's County, Oxon Hill High School in southern Prince George's County, and Charles Herbert Flowers High School in central Prince George's County. Students attend the center that serves their legal residence. Transportation is provided for all students. Each school is a four-year comprehensive high school, as well as a Science and Technology Center.

Sources: en.wikipedia.org

Further detail

== Principle == Modified Russell–Movat staining highlights numerous tissue components in histological slides. It is obtained by a mix of five stains: alcian blue, Verhoeff hematoxylin and crocein scarlet combined with acidic fuchsine and saffron. At pH 2.5, alcian blue is fixed by electrostatic binding with the acidic mucopolysaccharides. The Verhoeff hematoxylin has a high affinity for nuclei and elastin fibers, negatively charged. The combination of crocein scarlet with acidic fuchsine stains acidophilic tissue components in red. Then, collagen and reticulin fibers are unstained by a reaction with phosphotungstic acid and stained in yellow by saffron.

=== Semiconductors === In 2014, researchers proved that they can create electrically conductive thin films of MOFs (Cu3(btc)2 (also known as HKUST-1; BTC, benzene-1,3,5-tricarboxylic acid) infiltrated with the molecule 7,7,8,8-tetracyanoquinododimethane) that could be used in applications including photovoltaics, sensors, and electronic materials and a path toward creating semiconductors. The team demonstrated tunable, air-stable electrical conductivity with values as high as 7 siemens per meter, comparable to bronze. Ni3(2,3,6,7,10,11-hexaiminotriphenylene)2 was shown to be a metal-organic graphene analogue that has a natural band gap, making it a semiconductor, and is able to self-assemble. It is an example of conductive metal-organic framework. It represents a family of similar compounds. Because of the symmetry and geometry in 2,3,6,7,10,11-hexaiminotriphenylene (hitp), the overall organometallic complex has an almost fractal nature that allows it to perfectly self-organize. By contrast, graphene must be doped to give it the properties of a semiconductor. Ni3(hitp)2 pellets had a conductivity of 2 S/cm, a record for a metal-organic compound. In 2018, researchers synthesized a two-dimensional semiconducting MOF (Fe3(THT)2(NH4)3, also known as THT, 2,3,6,7,10,11-triphenylenehexathiol) and showed high electric mobility at room temperature. In 2020 the same material was integrated in a photo-detecting device, detecting a broad wavelength range from UV to NIR (400–1575 nm).

== Mechanism == The enzyme uses pyridoxal phosphate (PLP), the active form of vitamin B6, as a cofactor. PLP is essential to the mechanism of decarboxylation in AADC. In the active enzyme, PLP is bound to lysine-303 of AADC as a Schiff base. Upon substrate binding, Lys-303 is displaced by the substrate's amine. This positions the carboxylate of the substrate within the active site such that decarboxylation is favored. Decarboxylation of the substrate produces a quinonoid intermediate, which is subsequently protonated to produce a Schiff base adduct of PLP and the decarboxylated product. Lys-303 can then regenerate the original Schiff base, releasing the product while retaining PLP. Probing this PLP-catalyzed decarboxylation, it has been discovered that there is a difference in concentration and pH dependence between substrates. DOPA is optimally decarboxylated at pH 6.7 and a PLP concentration of 0.125 mM, while the conditions for optimal 5-HTP decarboxylation were found to be pH 8.3 and 0.3 mM PLP.

Following Geoffrey Howe's resignation speech in November 1990, Heseltine challenged Thatcher for the party leadership, polling well enough to deny her an outright victory on the first ballot. Following Thatcher's subsequent resignation, Heseltine lost to Major on the second ballot, but returned to the Cabinet in his former post of Environment Secretary when Major became prime minister. As a key ally of Major, Heseltine was appointed President of the Board of Trade and Secretary of State for Trade and Industry following the 1992 general election. He supported Major when his leadership was challenged in 1995, and was promoted to Deputy Prime Minister and First Secretary of State. He declined to seek the leadership of the party following Major's 1997 election defeat, and served in Major's shadow cabinet as Deputy Leader of the Opposition, Shadow Chancellor of the Duchy of Lancaster and Shadow Secretary of State for Trade and Industry while the leadership election to succeed him was taking place. Heseltine was created a life peer in 2001 and has remained a vocal advocate of modernisation within the party. He has continued to make political interventions, criticising Brexit and Boris Johnson following the 2016 Brexit referendum result. In 2019, Heseltine had the whip suspended after saying he would vote for the Liberal Democrats, rather than the Conservatives, at the 2019 European Parliament election. Heseltine had the whip restored in July 2024.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.

Is SR9009 approved for human use?

No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.

Why is SR9009 banned in sport?

The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.

How is SR9009 measured?

Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.

Network